The mortality rate of patients with sepsis-induced immunosuppression is relatively high,especially for those with secondary infections and prolonged duration of immunosuppression. To improve clinical outcomes for patients with sepsis-induced immunosuppression, it is critical to identify risk factors associated with the disease that can be used to identify potential therapeutic agents to control those with sepsis-induced immunosuppression.Some of the questions we will explore include: – Can the risk factors for sepsis-induced immunosuppression be completely resolved through multi-omics (metabolomics, proteomics and genomics), and can the occurrence or progression of sepsis-induced immunosuppression be improved by intervening in these risk factors? – Are there relevant biomarkers that predict sepsis to develop into sepsis-induced immunosuppression? – What other genetic variants or biomarkers may affect the survival of patients with sepsis-induced immunosuppression? The project’s findings could lead to new treatments for sepsis-induced immunosuppression and reduce the number of deaths caused by these diseases. We expect this study to take approximately 3 years to complete and to publish multiple results in journals.In recent years, more and more studies have analyzed multi-omics data of patients by bioinformatics means to finally screen out predictive markers closely related to acute and critical illness. The project also plans to use this approach to identify risk factors and biomarkers for immunosuppression in sepsis.
